Comparison of short- and long-term cyclosporine A therapy in chronic idiopathic urticaria
Related Experiment Video
Updated: Aug 23, 2026
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
E Bulbul Baskan1, S Tunali, T Turker
1Dermatology Department, Uludag University Medical Faculty, Bursa, Turkey. ezbaskan@ttnet.net.tr
Background:
Chronic idiopathic urticaria is sometimes difficult to treat, with little response to antihistamine therapy.
Objective:
In a limited number of severe chronic idiopathic urticaria patients, cyclosporine A (CsA) therapy was found to be effective. In this study, we compared the clinical efficacy and safety of short- and long-term CsA applications.
Methods:
Twenty patients with severe disease, unresponsive to antihistamines and showing a positive autologous serum skin test (ASST) were randomized to 4 mg/kg per day of CsA for 4 or 12 weeks. The clinical efficacy was measured with a daily activity score of weal numbers and itch (UAS). The two groups were compared in terms of mean reduction in UAS and ASST response to pre-and post-treatment sera.
Results:
The clinical improvement was dramatic in the first month of treatment in both groups. There was no significant difference in the frequency of responses, side effects and the reduction of UAS in either group.
Conclusion:
The preliminary results of our study suggest that CsA is clinically effective for chronic urticaria. The prolonged use of this therapy for more than 1 month provides little benefit in the clinical improvement.
